Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Chia, SKL; Martin, M; Holmes, FA; Ejlertsen, B; Delaloge, S; Moy, B; Iwata, H; von Minckwitz, G; Mansi, J; Barrios, CH; Gnant, M; Tomasevic, Z; Denduluri, N; Separovic, R; Kim, SB; Jakobsen, EH; Harvey, V; Robert, N; Smith, J; Harker, G; Zhang, B; Eli, LD; Ye, YN; Lalani, AS; Buyse, M; Chan, A.

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

BREAST CANCER RESEARCH. 2019; 21: Nº de citas: 21 [doi:10.1186/s13058-019-1115-2]

Lope, V; Martin, M; Castello, A; Ruiz, A; Casas, AM; Baena-Canada, JM; Antolin, S; Ramos-Vazquez, M; Garcia-Saenz, JA; Munoz, M; Lluch, A; de Juan-Ferre, A; Jara, C; Sanchez-Rovira, P; Anton, A; Chacon, JI; Arcusa, A; Jimeno, MA; Bezares, S; Vioque, J; Carrasco, E; Perez-Gomez, B; Pollan, M.

Overeating, caloric restriction and breast cancer risk by pathologic subtype: the EPIGEICAM study

Scientific Reports. 2019; 9: Nº de citas: 29 [doi:10.1038/s41598-019-39346-4]

Press, MF; Seoane, JA; Curtis, C; Quinaux, E; Guzman, R; Sauter, G; Eiermann, W; Mackey, JR; Robert, N; Pienkowski, T; Crown, J; Martin, M; Valero, V; Bee, V; Ma, YL; Villalobos, I; Slamon, DJ.

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines

JAMA Oncology. 2019; 5(3): 366-375 Nº de citas: 29 [doi:10.1001/jamaoncol.2018.6012]

Vidal, J; Bellosillo, B; Vivas, CS; Garcia-Alfonso, P; Carrato, A; Cano, MT; Garcia-Carbonero, R; Elez, E; Losa, F; Massuti, B; Valladares-Ayerbes, M; Vieitez, JM; Manzano, JL; Azuara, D; Gallego, J; Pairet, S; Capella, G; Salazar, R; Tabernero, J; Aranda, E; Montagut, C.

Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy

ANNALS OF ONCOLOGY. 2019; 30(3): 439-446 Nº de citas: 20 [doi:10.1093/annonc/mdz005]

Borrero-Palacios, A; Cebrian, A; del Pulgar, MTG; Garcia-Carbonero, R; Garcia, P; Aranda, E; Elez, E; Lopez-Lopez, R; Cervantes, A; Valladares, M; Nadal, C; Vieitez, JM; Guillen-Ponce, C; Rodriguez, J; Hernandez, I; Garcia, JL; Vega-Bravo, R; Puime-Otin, A; Martinez-Useros, J; Del Puerto-Nevado, L; Rincon, R; Rodriguez-Remirez, M; Rojo, F; Garcia-Foncillas, J.

Combination of KIR2DS4 and Fc gamma RIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

Scientific Reports. 2019; 9: Nº de citas: 11 [doi:10.1038/s41598-019-39291-2]

de Bono, JS; De Giorgi, U; Rodrigues, DN; Massard, C; Bracarda, S; Font, A; Arija, JAA; Shih, KC; Radavoi, GD; Xu, N; Chan, WY; Ma, H; Gendreau, S; Riisnaes, R; Patel, PH; Maslyar, DJ; Jinga, V.

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss

CLINICAL CANCER RESEARCH. 2019; 25(3): 928-936 Nº de citas: 257 [doi:10.1158/1078-0432.CCR-18-0981]

Ruiz-Borrego, M; Jimenez, B; Antolin, S; Garcia-Saenz, JA; Corral, J; Jerez, Y; Trigo, J; Urruticoechea, A; Colom, H; Gonzalo, N; Munoz, C; Benito, S; Caballero, R; Bezares, S; Carrasco, E; Rojo, F; Martin, M.

A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012-12 (EDALINE) study

INVESTIGATIONAL NEW DRUGS. 2019; 37(1): 98-108 Nº de citas: 55 [doi:10.1007/s10637-018-0614-9]

Font, A; Luque, R; Villa, JC; Domenech, M; Vazquez, S; Gallardo, E; Virizuela, JA; Beato, C; Morales-Barrera, R; Gelabert, A; Macia, S; Puente, J; Rubio, G; Maldonado, X; Perez-Valderrama, B; Pinto, A; Calvo, OF; Grande, E; Garde-Noguera, J; Fernandez-Parra, E; Arranz, JA.

The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)

TARGETED ONCOLOGY. 2019; 14(1): 15-32 Nº de citas: 11 [doi:10.1007/s11523-019-00619-7]

Gorbunova, V; Beck, JT; Hofheinz, RD; Garcia-Alfonso, P; Nechaeva, M; Gracian, AC; Mangel, L; Fernandez, EE; Deming, DA; Ramanathan, RK; Torres, AH; Sullivan, D; Luo, Y; Berlin, JD.

A phase 2 randomised study of veliparib plus FOLFIRI +/- bevacizumab versus placebo plus FOLFIRI +/- bevacizumab in metastatic colorectal cancer

BRITISH JOURNAL OF CANCER. 2019; 120(2): 183-189 Nº de citas: 53 [doi:10.1038/s41416-018-0343-z]

Macarulla, T; Pazo-Cid, R; Guillen-Ponce, C; Lopez, R; Vera, R; Reboredo, M; Martin, AM; Rivera, F; Beveridge, RD; La Casta, A; Valades, JM; Martinez-Galan, J; Ales, I; Sastre, J; Perea, S; Hidalgo, M.

Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2

JOURNAL OF CLINICAL ONCOLOGY. 2019; 37(3): 230-238 Nº de citas: 74 [doi:10.1200/JCO.18.00089]

Johnston, S; Martin, M; Di Leo, A; Im, SA; Awada, A; Forrester, T; Frenzel, M; Hardebeck, MC; Cox, J; Barriga, S; Toi, M; Iwata, H; Goetz, MP.

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

Npj Breast Cancer. 2019; 5: Nº de citas: 543 [doi:10.1038/s41523-018-0097-z]

Atrafi, F; Groen, HJM; Byers, LA; Garralda, E; Lolkema, MP; Sangha, RS; Viteri, S; Chae, YK; Camidge, DR; Gabrail, NY; Hu, BB; Tian, T; Nuthalapati, S; Hoening, E; He, L; Komarnitsky, P; Calles, A.

A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors

CLINICAL CANCER RESEARCH. 2019; 25(2): 496-505 Nº de citas: 40 [doi:10.1158/1078-0432.CCR-18-2014]

Lopez-Muniz, JIC; Merino, LD; Gregori, JG; Duenas, EM; Oliveira, M; Palmer, MAS; Lopez, IA; Novoa, SA; Ezquerra, MB; Cobo, SLT.

SEOM clinical guidelines in advanced and recurrent breast cancer (2018)

Clinical & Translational Oncology. 2019; 21(1): 31-45 Nº de citas: 14 [doi:10.1007/s12094-018-02010-w]

Yoshino, T; Portnoy, DC; Obermannova, R; Bodoky, G; Prausova, J; Garcia-Carbonero, R; Ciuleanu, T; Garcia-Alfonso, P; Cohn, AL; Van Cutsem, E; Yamazaki, K; Lonardi, S; Muro, K; Kim, TW; Yamaguchi, K; Grothey, A; O'Connor, J; Taieb, J; Wijayawardana, SR; Hozak, RR; Nasroulah, F; Tabernero, J.

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE-a global phase III study

ANNALS OF ONCOLOGY. 2019; 30(1): 124-131 Nº de citas: 59 [doi:10.1093/annonc/mdy461]

Di Leo, A; O'Shaughnessy, J; Sledge GW Jr; Martin, M; Lin, Y; Frenzel, M; Hardebeck, MC; Smith, IC; Llombart-Cussac, A; Goetz, MP; Johnston, S.

Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy

Npj Breast Cancer. 2018; 4: 41-41 Nº de citas: 52 [doi:10.1038/s41523-018-0094-2]

Templeton, AJ; Rodriguez-Lescure, A; Ruiz, A; Alba, E; Calvo, L; Ruiz-Borrego, M; Santaballa, A; Rodriguez, CA; Crespo, C; Ramos, M; Gracia-Marco, JM; Lluch, A; Alvarez, I; Casas, MI; Sanchez-Arago, M; Caballero, R; Carrasco, E; Amir, E; Martin, M; Ocana, A; GEICAM Study Investigators.

Prognostic role for the derived neutrophil-to-lymphocyte ratio in early breast cancer: a GEICAM/9906 substudy

Clinical & Translational Oncology. 2018; 20(12): 1548-1556 Nº de citas: 13 [doi:10.1007/s12094-018-1885-5]

Caries, J; Castellano, D; Mendez-Vidal, MJ; Mellado, B; Saez, MI; del Alba, AG; Perez-Gracia, JL; Jimenez, J; Suarez, C; Sepulveda, JM; Manneh, R; Porras, I; Lopez, C; Morales-Barrera, R; Arranz, JA.

Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer

Clinical Genitourinary Cancer. 2018; 16(6): 1133-1139 Nº de citas: 18 [doi:10.1016/j.clgc.2018.07.013]

Sharma, P; Lopez-Tarruella, S; Garcia-Saenz, JA; Khan, QJ; Gomez, HL; Prat, A; Moreno, F; Jerez-Gilarranz, Y; Barnadas, A; Picornell, AC; del Monte-Millan, M; Gonzalez-Rivera, M; Massarrah, T; Pelaez-Lorenzo, B; Palomero, MI; González Del Val R; Cortes, J; Fuentes-Rivera, H; Morales, DB; Marquez-Rodas, I; Perou, CM; Lehn, C; Wang, YY; Klemp, JR; Mammen, JV; Wagner, JL; Amin, AL; O'Dea, AP; Heldstab, J; Jensen, RA; Kimler, BF; Godwin, AK; Martin, M.

Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

CLINICAL CANCER RESEARCH. 2018; 24(23): 5820-5829 Nº de citas: 96 [doi:10.1158/1078-0432.CCR-18-0585]